By Josh Beckerman
Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.
The drug was approved for treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart-failure visits.
Cantor Fitzgerald wrote that "The most important thing is that it's approved with a broad label: by this, we mean mortality language is in fact included on the front page" and that the language about urgent heart failure visits is a differentiator compared with other products.
Amvuttra was previously approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
March 20, 2025 18:47 ET (22:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.